Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib
This study provides access to an experimental drug called daraxonrasib for patients with pancreatic cancer that has spread to other parts of the body. It is designed for people who have already tried other treatments but have no other suitable options available to them.
This program is for adults aged 18 and older who remain active and physically fit for daily tasks. You must have already tried chemotherapy for your pancreatic cancer and be unable to join other ongoing clinical trials for this specific drug.
Participants will receive daraxonrasib, an experimental medicine designed to stop cancer cells from growing. Your medical team will monitor you closely to track your response to the treatment and ensure your safety.
The program is currently open and available. It is being offered at specific medical locations in Daphne and Mobile, Alabama, as well as Anchorage, Alaska.
- 1This is an 'Expanded Access' program, which helps patients get experimental treatments when other options have been exhausted.
- 2You must have a history of prior chemotherapy treatment for your cancer to be eligible.
- 3Certain health conditions, such as heart problems or active infections, may prevent you from participating in this program.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.